scholarly journals The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial: Rationale and Design

2005 ◽  
Vol 28 (4) ◽  
pp. 331-338 ◽  
Author(s):  
Toshio OGIHARA ◽  
Masunori MATSUZAKI ◽  
Hiroaki MATSUOKA ◽  
Kazuaki SHIMAMOTO ◽  
Kazuyuki SHIMADA ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Cardiovascular Events ◽  
Therapy Of Hypertension

scholarly journals Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial

2012 ◽  
Vol 35 (4) ◽  
pp. 441-448 ◽  
Author(s):  
Toshio Ogihara ◽  
◽  
Masunori Matsuzaki ◽  
Seiji Umemoto ◽  
Hiromi Rakugi ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Cardiovascular Events ◽  
The Elderly ◽  
Therapy Of Hypertension

552 COMBINATION THERAPY IN HYPERTENSION WITH CKD - A SUBANALYSIS OF COMBINATION THERAPY OF HYPERTENSION TO PREVENT CARDIOVASCULAR EVENTS (COPE) TRIAL

2012 ◽  
Vol 30 ◽  
pp. e162
Author(s):  
Hiromi Rakugi ◽  
Toshio Ogihara ◽  
Masunori Matsuzaki ◽  
Seiji Umemoto ◽  
Yasuo Ohashi ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Cardiovascular Events ◽  
Therapy Of Hypertension

scholarly journals Combination therapy for hypertension in patients with CKD: a subanalysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events trial

2013 ◽  
Vol 36 (11) ◽  
pp. 947-958 ◽  
Author(s):  
Hiromi Rakugi ◽  
◽  
Toshio Ogihara ◽  
Seiji Umemoto ◽  
Masunori Matsuzaki ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Cardiovascular Events ◽  
Therapy Of Hypertension

scholarly journals Co-Amorphous Simvastatin-Nifedipine with Enhanced Solubility for Possible Use in Combination Therapy of Hypertension and Hypercholesterolemia

Molecules ◽  
2018 ◽  
Vol 23 (9) ◽  
pp. 2161 ◽  
Author(s):  
Cecilia Martínez-Jiménez ◽  
Jorge Cruz-Angeles ◽  
Marcelo Videa ◽  
Luz Martínez
Keyword(s):  
Combination Therapy ◽  
Amorphous State ◽  
Active Pharmaceutical Ingredient ◽  
Molar Ratio ◽  
Amorphous System ◽  
Enhanced Solubility ◽  
Significant Area ◽  
One Year ◽  
The Stability ◽  
Therapy Of Hypertension

The high index of simultaneous incidence of hypertension and hypercholesterolemia in the population of many countries demands the preparation of more efficient drugs. Therefore, there is a significant area of opportunity to provide as many alternatives as possible to treat these illnesses. Taking advantage of the solubility enhancement that can be achieved when an active pharmaceutical ingredient (API) is obtained and stabilized in its amorphous state, in the present work, new drug-drug co-amorphous formulations (Simvastatin SIM- Nifedipine NIF) with enhanced solubility and stability were prepared and characterized. Results show that the co-amorphous system (molar ratio 1:1) is more soluble than the pure commercial APIs studied separately. Aqueous dissolution profiles showed increments of solubility of 3.7 and 1.7 times for SIM and NIF, correspondingly, in the co-amorphous system. The new co-amorphous formulations, monitored in time, (molar fractions 0.3, 0.5 and 0.7 of SIM) remained stable in the amorphous state for more than one year when stored at room temperature and did not show any signs of crystallization when re-heating. Inspection on the remainder of a sample after six hours of dissolution showed no recrystallization, confirming the stability of co-amorphous system. The enhanced solubility of the co-amorphous formulations makes them promising for simultaneously targeting of hypertension and hypercholesterolemia through combination therapy.

Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease

2016 ◽  
Vol 22 (2) ◽  
pp. 142-152 ◽  
Author(s):  
Qiang Niu ◽  
Zhongsu Wang ◽  
Yong Zhang ◽  
Jiangrong Wang ◽  
Pei Zhang ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Combination Therapy ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Cardiovascular Events ◽  
Cochrane Library ◽  
Major Adverse Cardiovascular Events ◽  
Increased Risk ◽  
Artery Disease

Background: Published data indicated that combination use of clopidogrel and proton pump inhibitors (PPIs) may increase the incidence of major adverse cardiovascular events (MACEs). This has been a highly controversial topic for years. Design: The present study was performed to evaluate whether combination therapy of clopidogrel and PPIs is associated with increased risk of MACEs than with clopidogrel alone in patients with coronary artery disease. Methods: A systematic search of MEDLINE, EMBASE, and the Cochrane Library was conducted for studies recording the occurrence of MACEs in patients with exposure to concomitant use of clopidogrel and PPIs up to February 2015. Odds ratios (ORs) were combined using a random-effects model. Results: Patients receiving combination therapy with PPIs and clopidogrel were at significantly increased risk of MACEs (OR: 1.42; 95% confidence interval [CI]: 1.30-1.55). Adding a PPI to clopidogrel treatment was associated with a higher rate of MACE occurrence in rapid metabolizers (RMs, *1/*1) of CYP2C19 (OR: 1.42; 95% CI: 1.12-1.81), but there was no obviously increased rate (OR: 1.43; 95% CI: 0.89-2.28) in decreased metabolizers (with 1 or 2 loss-of-function allele). The increased risk of MACEs was similar in 4 classes of PPIs (omeprazole, lansoprazole, esomeprazole, and pantoprazole), but rabeprazole (OR: 1.03; 95% CI: 0.55-1.95) wasn’t. Conclusion: The combination use of clopidogrel and certain types of PPIs (omeprazole, lansoprazole, esomeprazole, pantoprazole) increases the risk of MACE in patients with coronary artery disease. Only in the RMs of CYP2C19, PPIs were associated with significantly increased MACE in patients coadministered with clopidogrel.

Sign in / Sign up

Export Citation Format

Share Document